Home LiteratureArticle Details
PMID: 11734627 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Zhu CB, Zhu L, Holz-Smith S, Matthews TJ, Chen CH

Abstract

Neutralization of HIV-1 primary isolates has been a tremendous challenge for AIDS vaccine development. Here, we identify a single amino acid change (T198P) in gp120 that alters the neutralization sensitivity of the primary isolate DH012 to antibodies against multiple neutralization epitopes that include the V3, CD4-induced, and CD4 binding sites in gp120. This mutation is located in the V1/V2 stem region that forms the third beta strand (beta3) of the bridging sheet of gp120. The conformation of variable loops, especially V1/V2 and V3, was proposed to regulate the accessibility of these neutralization epitopes. The results of this study indicate a direct association between the V1/V2 and V3 loops of DH012 gp120. The single amino acid mutation T198P in the beta3 severely compromises the interaction between the V1/V2 and V3 loops. These results suggest that interaction of V1/V2 and V3 can mask the neutralization epitopes and that the beta3 plays a critical role in determining the neutralization sensitivity by modulating the interaction. This study provides an insight into why primary isolates are relatively resistant to antibody neutralization and might facilitate the development of anti-HIV strategies against HIV-1 infection.

MeSH Terms
Base Sequence Cell Line Cloning, Molecular DNA Primers Epitopes/immunology HIV Envelope Protein gp120/chemistry,genetics,immunology HIV-1/chemistry Humans Mutagenesis, Site-Directed Neutralization Tests Protein Conformation Recombinant Proteins/chemistry,genetics,immunology
Chemicals
DNA Primers Epitopes HIV Envelope Protein gp120 Recombinant Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Zhu C B
Department of Microbiology, Meharry Medical College, Nashville, TN 37208, USA.
Zhu L
Holz-Smith S
Matthews T J
Chen C H
References (30)
30 references, click to expand
  1. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    J Virol. 2000 Jan;74(1):254-63 PMID: 10590113
  2. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    J Virol. 1995 Jul;69(7):4413-22 PMID: 7769703
  3. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  4. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.
    J Virol. 2000 Oct;74(20):9749-54 PMID: 11000249
  5. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  6. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    J Virol. 1995 Oct;69(10):6191-8 PMID: 7545244
  7. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  8. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
    J Virol. 1997 Apr;71(4):2779-85 PMID: 9060632
  9. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  10. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  11. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
    J Infect Dis. 1998 Feb;177(2):310-9 PMID: 9466516
  12. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  13. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
    J Virol. 1998 Aug;72(8):6332-8 PMID: 9658072
  14. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    AIDS. 1998 Dec 24;12(18):2407-15 PMID: 9875578
  15. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    J Virol. 1999 Jul;73(7):5294-300 PMID: 10364275
  16. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
    J Virol. 1999 Oct;73(10):8873-9 PMID: 10482646
  17. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
    J Virol. 2000 Dec;74(24):11955-62 PMID: 11090196
  18. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.
    Antimicrob Agents Chemother. 2001 Jan;45(1):60-6 PMID: 11120945
  19. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35 PMID: 11153085
  20. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
    Structure. 2000 Dec 15;8(12):1329-39 PMID: 11188697
  21. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
    J Virol. 2001 Apr;75(7):3435-43 PMID: 11238869
  22. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    J Virol. 2001 Jun;75(12):5457-64 PMID: 11356952
  23. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.
    J Virol. 2001 Jul;75(14):6700-4 PMID: 11413338
  24. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  25. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  26. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    JAMA. 1994 Aug 10;272(6):475-80 PMID: 7913731
  27. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  28. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.
    Virology. 1995 Feb 1;206(2):878-84 PMID: 7856100
  29. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.
    J Virol. 1995 Jun;69(6):3771-7 PMID: 7538176
  30. Higher western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates.
    AIDS Res Hum Retroviruses. 2000 May 20;16(8):765-75 PMID: 10826483
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2001-12-18
Epub
2001-00-04
Pages
15227-32
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC65011
Subset
IM
Grants
NIAID NIH HHS · AI40856 · United States
NIAID NIH HHS · AI44281 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com